Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health鈥檚 integrated model鈥攔etail pharmacies, a leading PBM and a major insurer鈥攑roduces sprawling SEC documents that mix drug-pricing mechanics with insurance risk metrics. Finding where opioid litigation reserves sit in a 10-K or tracking when executives sell shares before material announcements can feel impossible.
Stock Titan solves that complexity. Our AI reads every page the moment a filing hits EDGAR, then serves concise answers to the questions investors actually ask, like 鈥淐VS Health SEC filings explained simply鈥� or 鈥淗ow do I read the CVS Health annual report 10-K simplified?鈥�. You鈥檒l see segment revenue, prescription volume trends, and medical loss ratios flagged automatically, alongside plain-language guidance for each section.
All filing types appear in one place and update in real time:
- CVS Health quarterly earnings report 10-Q filing with side-by-side KPI charts
- CVS Health 8-K material events explained within minutes of release
- CVS Health proxy statement executive compensation tables parsed and summarized
- CVS Health insider trading Form 4 transactions streamed live, plus alerts for CVS Health executive stock transactions Form 4
Need deeper context? Click 鈥淎I Review鈥� for CVS Health earnings report filing analysis or use the search bar for 鈥渦nderstanding CVS Health SEC documents with AI.鈥� Whether you鈥檙e modelling PBM margins, monitoring CVS Health Form 4 insider transactions real-time, or benchmarking cash flows, our expert narratives replace hours of manual reading with insights you can act on immediately.
Prem S. Shah, EVP and Group President at CVS Health (CVS), surrendered 6,995 shares on 08/31/2025 to satisfy withholding taxes from the vesting and settlement of a restricted stock unit award. The shares were recorded at a price of $73.15 and, after the transaction, Mr. Shah beneficially owned 60,631.677 shares directly. The Form 4 was signed on 09/02/2025 and reflects a routine insider tax-withholding disposition rather than an open-market sale.
Insider transaction: Tilak Mandadi, Executive Vice President and Chief Experience & Technology Officer at CVS Health (CVS), reported a transaction on 08/31/2025 in which 12,834 shares of CVS common stock were disposed at a price of $73.15 per share. The filing states these shares were surrendered to cover withholding taxes upon vesting and settlement of restricted stock units, a routine payroll tax withholding mechanism for equity compensation. Following the transaction Mandadi beneficially owns 63,952 shares directly.
Anne A. Finucane, a director of CVS Health (CVS), reported a sale of company stock that was filed on Form 4. The filing shows a transaction dated 08/20/2025 in which 7,500 shares of Common Stock were disposed of at a reported price of $71.02 per share under transaction code S(1). After the reported sale, the filing lists 22,156 shares beneficially owned indirectly through a trust. The form includes an explanatory note stating the sale was not timely reported due to an administrative error. The document is signed by Anne M. Finucane on 08/29/2025.
CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
FAQ
What is the current stock price of Cvs Health (CVS)?
What is the market cap of Cvs Health (CVS)?
